-transparent.png){kind=logo}
Vinblastine 5-day continuous infusion in metastatic renal-cell carcinoma was evaluated in a Phase II trial. The dosage varied from 1.4 to 1.6 mg/m2/day every 3 weeks according to previous treatment and performance status (PS). From September 1983 to January 1986, 25 consecutive patients entered the study; 21 were evaluable for response and 23 were evaluable for toxicity. The median number of cycles administered was three (range, one to six). One complete response (liver) lasting 5 months, one partial response (lung) lasting 3 months, 12 cases of stable disease, and seven progressions were noted. Toxicity (WHO criteria) was relevant and mainly hematological: one treatment-related death occurred. Vinblastine continuous infusion did not demonstrate significant antineoplastic activity against metastatic renal-cell carcinoma.
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
June 1984,
Cancer treatment reports,
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
February 1985,
Cancer treatment reports,
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
July 1995,
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
June 1994,
Cancer,
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
June 1995,
American journal of clinical oncology,
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
March 1990,
European journal of cancer (Oxford, England : 1990),
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
February 1985,
Cancer treatment reports,
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
January 1984,
Anticancer research,
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
July 1985,
Cancer,
D Crivellari, and
S Tumolo, and
S Frustaci, and
E Galligioni, and
F Figoli, and
G Lo Re, and
A Veronesi, and
S Monfardini
September 2006,
Investigational new drugs,
